Domestic revenues were $37.4 million for the third quarter and $105.4 million for the first nine months of 2009, both representing increases of 12 percent over the same periods the year before.
Third-quarter revenues reflect the launch of four new orthopedic implants and revenue for the first nine months reflects new revenues from Tutogen, which merged with RTI.
Read the release on RTI Biologics third-quarter revenue.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
